We analyzed PRAME transcript levels in cutaneous melanoma specimens bearing relevant signaling pathway mutations (Fig. 2) and observed no significant difference in PRAME expression in melanomas harboring mutant BRAF or NRAS genes compared with their wild-type counterparts (Fig. 2a). The gene discussed is NRAS; the disease is melanoma.